Featured Post
IIVS Partners with SkynFuture to Further In Vitro Research Techniques
September 18, 2023IIVS is pleased to announce a partnership with SkynFuture, a cosmetics and skincare brand within the UniAsia cosmetics company. IIVS and SkynFuture will collaborate to develop and optimize human-relevant research and testing methods to assess the safety and efficacy of skincare products, and conduct training and other activities to advance non-animal test methods in China. ...
Incorporating GIVIMP Recommendations into Method Development, Use, and Transfer
August 30, 2023The demand for toxicology data from human-relevant, New Approach Methodologies (NAMs) continues to increase. Fortunately, the scientific community has responded with new tools based on human tissues and cells. The creators of these systems and test methods utilizing them have invested in their development and also in studies designed to demonstrate their relevance, reproducibility, and transferability. Despite these efforts, scientific confidence in these methods at the regulatory level remains comparatively low. In order to bridge the gap between development and...
August 2023 Newsletter
August 24, 2023ToxTracker is a unique, stem-cell based assay which takes advantage of a Green Fluorescent Protein (GFP) reporter system to identify hazard and mode-of-action (MOA) of potentially genotoxic materials. On July 20th, IIVS was formally awarded ToxTracker Certification by Toxys, a Dutch Biotechnology company and the developers of the assay....
IIVS Acquires Licenses to Work with DEA Schedule I Materials
July 29, 2023IIVS is pleased to announce that our lab has acquired the necessary State and Federal licenses required to work with several materials and compounds listed on DEA Schedule 1. These include cannabis and Δ9-THC and related cannabinoids (DEA Drug Codes 7360 & 7370). Our state-of-the art exposure systems include the Vitrocell® VC-1 and Cloud which able to generate smoke and nebulize liquid formulations and permit IIVS to evaluate controlled substance-containing products for many respiratory endpoints, such as cytotoxicity, inflammatory response...
Multiscale Stiffness of Human Emphysematous Precision-Cut Lung Slices
May 22, 2023IIVS is excited to announce a new publication in Science with co-authors at Boston University and Mechanobiologix (Newton, MA, USA)! Abstract: Emphysema is a debilitating disease that remodels the lung leading to reduced tissue stiffness. Thus, understanding emphysema progression requires assessing lung stiffness at both the tissue and alveolar scales. Here, we introduce an approach to determine multiscale tissue stiffness and apply it to precision-cut lung slices (PCLS). First, we established a framework for measuring stiffness of thin, disk-like samples....
62nd Annual Meeting of the Society of Toxicology
March 14, 2023IIVS is looking forward to exhibiting at the 62nd Annual Meeting of the Society of Toxicology! If attending, please visit us during ToxExpo at booth #834. ...
IIVS and Toxys Enter Into Agreement to Offer ToxTracker® for In Vitro Genetic Toxicity Evaluation
March 9, 2023The Institute for In Vitro Sciences (IIVS) and Toxys have entered into a license agreement that allows IIVS to offer the ToxTracker® assay. ToxTracker is an innovative in vitroassay allowing identification of the genotoxic and potentially carcinogenic properties of novel and existing drugs, (agro)chemicals, cosmetics and other substances without the use of animal testing....
March 2023 Newsletter
March 1, 2023IIVS is pleased to share that the PMI In Vitro Alternatives Laboratory in Neuchâtel, Switzerland is now GIVIMP certified. Good In Vitro Method Practices (GIVIMP) is an OECD guidance document that provides a framework for quality standards specific to in vitro laboratory operations....
Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 2
February 16, 2023This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan)....
Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 1
February 7, 2023This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan)....